ClinicalTrials.gg
RecruitingNCT07863635Updated Nov 4, 2026

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations

A Phase 4 interventional study of mRNA-1273 and mRNA-1283 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Recruiting at 5 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 4, 2026Now RecruitingEnrollment updated+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Planned enrollment
17th of 36
600 · median 499
Started
2026
the only one that year
Phase 4
7 of 36
2 open now
Registered
36th of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 17th largest by planned enrollment, is the only one that started in 2026, is one of 7 in phase 4, and was the 36th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1283 and mRNA-1273 (variant formulations) within the current epidemiological environment

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1283
  • SARS-CoV-2
  • mRNA vaccine
  • Coronavirus
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
  • SPIKEVAX®
  • mNEXSPIKE®
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's planned enrollment of 600 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥65 years of age at the time of signing the OR ≥12 to \<65 years of age at the time of signing the informed consent with at least 1 risk factor for severe outcomes from COVID-19.
  • Female participants of may be enrolled in the study if not pregnant or breastfeeding, subject to other criteria specified in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • History of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 months prior to enrollment.
  • Acutely ill or febrile within 72 hours prior to or at Day 1.
  • History of a diagnosis or conditions that in the Investigator's opinion could affect participant's safety, assessment of endpoints, assessment of immune response, or adherence to study procedures.
  • Reported history of congenital or acquired immunodeficiency, condition, asplenia, or recurrent severe infections.
  • History of coagulopathy or bleeding disorder that is considered a to IM injection or phlebotomy.
  • Receipt of any of the following:

    • COVID-19 vaccine within 3 months prior to enrollment,
    • Any licensed non COVID-19 vaccine within 28 days before or planned receipt within 28 days after the study intervention, except an influenza vaccine, which may be given 14 days before or after receipt of the study intervention,
    • Systemic immunosuppressive treatment within 180 days prior to the Screening or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study,
    • Systemic immunoglobulins, long-acting biological therapies that affect immune responses, or blood products within 90 days prior to the Day 1 Visit or plans for receipt during the study.

Note: Additional protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    mRNA-1273 (Variant Formulation)

    Participants will receive a single intramuscular (IM) injection of mRNA-1273 on Day 1.

    Biological: mRNA-1273

  • Experimental
    mRNA-1283 (Variant Formulation)

    Participants will receive a single IM injection of mRNA-1283 on Day 1.

    Biological: mRNA-1283

Interventions

  • BiologicalmRNA-1273

    Sterile liquid for injection

    Also known as: SPIKEVAX®

  • BiologicalmRNA-1283

    Sterile liquid for injection

    Also known as: mNEXSPIKE®

07

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant Formulation

    Time frame: Day 29

  2. Geometric Mean Fold Rise (GMFR) of Neutralizing Antibody (nAb) Against Vaccine-matched Variant Formulation

    Time frame: Day 29

Secondary outcomes

  1. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Day 1 through Day 29

  2. Number of Participants with Serious AEs (SAEs), AEs Leading to Study Withdrawal, and AEs of Special Interest (AESIs)

    Time frame: Day 1 through Day 29/End of Study (EOS)

  3. Seroresponse Rate (SRR) of Neutralizing Antibody (nAb)

    Time frame: Day 29

08

Study locations

5 of 5 sites recruiting
  • Delricht Research @ Overland
    Overland Park, Kansas 66209, United States
    Recruiting
  • Delricht Research @ Louisville
    Louisville, Kentucky 40205, United States
    Recruiting
  • Delricht Research @ Charlotte
    Charlotte, North Carolina 28210, United States
    Recruiting
  • Delricht Research @ Magnolia Family Medicine
    Hendersonville, Tennessee 37075, United States
    Recruiting
  • Delricht Research @ Zomnir Family Medicine
    Prosper, Texas 75078, United States
    Recruiting
09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 2 months after the start.

Of 44 industry-sponsored phase 4 interventional studies under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 2 months is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jan 2027 → Dec 2026 and completion Jan 2027 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartActual
Oct 9, 2026
Primary completionEst.
Dec 11, 2026was Jan 2027
CompletionEst.
Dec 11, 2026was Jan 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
3 sites added, 3 sites removed. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Delricht Research @ Magnolia Family Medicine · Hendersonville, United Statesno status→Recruiting
  • Delricht Research @ Zomnir Family Medicine · Prosper, United Statesno status→Recruiting
Show 3 added (3 United States)
  • Delricht Research @ Overland · Overland Park, United States
  • Delricht Research @ Louisville · Louisville, United States
  • Delricht Research @ Charlotte · Charlotte, United States
Show 3 removed
  • Delricht Research @ Concierge and Direct Primary Care · Overland Park, United States
  • Delricht Research @ Derby City Direct Primary Care · Louisville, United States
  • Delricht Research @ Olabisi Badmus · Charlotte, United States
Oct 27, 2026
Primary completion
Jan 9, 2027→Dec 11, 2026
Oct 27, 2026
Study completion
Jan 9, 2027→Dec 11, 2026
Oct 27, 2026
Enrollment
300→600
Nov 4, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedHistory of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 63 months prior to enrollment.
  • EditedCOVID-19 vaccine within 63 months prior to enrollment,
Nov 4, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedGeometric Mean Titer (GMT) onof Neutralizing Antibody (nAb) Against Vaccine-matched Variant FormulationTime frame: Day 29
  • EditedGeometric Mean Fold Rise (GMFR) onof Neutralizing Antibody (nAb) Against Vaccine-matched Variant FormulationTime frame: Day 29
Nov 4, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedSeroresponse Rate (SRR) of Neutralizing Antibody (nAb)Time frame: Day 29
Nov 4, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 3 updates
  1. Nov 4, 2026
    Enrollment 300→600
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedHistory of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 63 months prior to enrollment.
    • EditedCOVID-19 vaccine within 63 months prior to enrollment,
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedGeometric Mean Titer (GMT) onof Neutralizing Antibody (nAb) Against Vaccine-matched Variant FormulationTime frame: Day 29
    • EditedGeometric Mean Fold Rise (GMFR) onof Neutralizing Antibody (nAb) Against Vaccine-matched Variant FormulationTime frame: Day 29
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedSeroresponse Rate (SRR) of Neutralizing Antibody (nAb)Time frame: Day 29
    + 1 other change: verification date
  2. Oct 27, 2026
    Not yet recruiting→Recruiting
    3 sites added, 3 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Delricht Research @ Magnolia Family Medicine · Hendersonville, United Statesno status→Recruiting
    • Delricht Research @ Zomnir Family Medicine · Prosper, United Statesno status→Recruiting
    Show 3 added (3 United States)
    • Delricht Research @ Overland · Overland Park, United States
    • Delricht Research @ Louisville · Louisville, United States
    • Delricht Research @ Charlotte · Charlotte, United States
    Show 3 removed
    • Delricht Research @ Concierge and Direct Primary Care · Overland Park, United States
    • Delricht Research @ Derby City Direct Primary Care · Louisville, United States
    • Delricht Research @ Olabisi Badmus · Charlotte, United States
    Primary completion Jan 9, 2027→Dec 11, 2026
    Study completion Jan 9, 2027→Dec 11, 2026
    + 1 other change: verification date
  3. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863635
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 9, 2026
Primary completion
Dec 11, 2026 (estimated)
Completion
Dec 11, 2026 (estimated)
Last update
Nov 4, 2026

Study contacts

Moderna WeCareTeam
Contact
WeCareClinicalTrials@modernatx.com
+1-866-663-3762

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · MRNA-1283

Start the discussion